EA201100626A1 - Лечение рака с помощью ионизирующего облучения и иммуноцитокинов - Google Patents

Лечение рака с помощью ионизирующего облучения и иммуноцитокинов

Info

Publication number
EA201100626A1
EA201100626A1 EA201100626A EA201100626A EA201100626A1 EA 201100626 A1 EA201100626 A1 EA 201100626A1 EA 201100626 A EA201100626 A EA 201100626A EA 201100626 A EA201100626 A EA 201100626A EA 201100626 A1 EA201100626 A1 EA 201100626A1
Authority
EA
Eurasian Patent Office
Prior art keywords
immunocytokins
cancer
help
treatment
ionizing radiation
Prior art date
Application number
EA201100626A
Other languages
English (en)
Russian (ru)
Inventor
Томас Уикхем
Ульрике Гнад-Фогт
Штефан Г. Клинц
Силвиа А. Холден
Карл Йозеф Каллен
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201100626A1 publication Critical patent/EA201100626A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201100626A 2008-10-21 2009-10-21 Лечение рака с помощью ионизирующего облучения и иммуноцитокинов EA201100626A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10714608P 2008-10-21 2008-10-21
PCT/EP2009/007533 WO2010046097A1 (en) 2008-10-21 2009-10-21 Cancer treatments with radiation and immunocytokines

Publications (1)

Publication Number Publication Date
EA201100626A1 true EA201100626A1 (ru) 2011-12-30

Family

ID=41510762

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100626A EA201100626A1 (ru) 2008-10-21 2009-10-21 Лечение рака с помощью ионизирующего облучения и иммуноцитокинов

Country Status (12)

Country Link
US (1) US20100330029A1 (enExample)
EP (1) EP2337579A1 (enExample)
JP (1) JP2012506394A (enExample)
KR (1) KR20110086101A (enExample)
CN (1) CN102196815A (enExample)
AU (1) AU2009306711A1 (enExample)
BR (1) BRPI0919857A2 (enExample)
CA (1) CA2741130A1 (enExample)
EA (1) EA201100626A1 (enExample)
MX (1) MX2011004193A (enExample)
WO (1) WO2010046097A1 (enExample)
ZA (1) ZA201103726B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015124297A1 (en) * 2014-02-19 2015-08-27 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
US9861833B1 (en) * 2017-03-30 2018-01-09 Norman H. Anderson Methods of treating melanoma
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN112768029B (zh) * 2020-12-27 2023-10-13 上海市东方医院(同济大学附属东方医院) 一种基于单细胞测序的组合用药推荐设备、方法及介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020110538A1 (en) * 1999-12-28 2002-08-15 Health Research, Inc. Methods and products for tumor immunotherapy using cytokines
CZ2003214A3 (cs) * 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
US20060263368A1 (en) * 2005-01-10 2006-11-23 Research Development Foundation Targeted chimeric molecules for cancer therapy
SI1966238T1 (sl) * 2005-12-30 2012-08-31 Merck Patent Gmbh Variante interlevkina-12P40 z izboljšano stabilnostjo

Also Published As

Publication number Publication date
KR20110086101A (ko) 2011-07-27
CN102196815A (zh) 2011-09-21
US20100330029A1 (en) 2010-12-30
ZA201103726B (en) 2012-01-25
BRPI0919857A2 (pt) 2015-12-15
WO2010046097A1 (en) 2010-04-29
JP2012506394A (ja) 2012-03-15
AU2009306711A1 (en) 2010-04-29
CA2741130A1 (en) 2010-04-29
MX2011004193A (es) 2011-05-24
EP2337579A1 (en) 2011-06-29

Similar Documents

Publication Publication Date Title
CY1123258T1 (el) Μεθοδος θεραπειας για τον καρκινο
MX2020009773A (es) Terapia de combinacion.
SG10201902664RA (en) Combination therapy for treating cancer
CY1115782T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
MXPA05011656A (es) Combinaciones para el tratamiento de enfermedades que implican proliferacion, migracion o apoptosis celulares de celulas de mieloma, o angiogenesis.
WO2011146777A3 (en) Device and method for providing a synergistic combination of phototherapy and a non-light energy modality to the brain
PH12015502260B1 (en) C. novyi for the treatment of solid tumors in humans
MX2020001727A (es) Terapia de combinacion.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
UA86586C2 (ru) Комбинация для лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
EA201001853A1 (ru) Фармацевтическая комбинация
EA202192964A1 (ru) Комбинированная терапия
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
PH12021551276A1 (en) Combination therapy for the treatment of cancer
MX2025008270A (es) Uso prolongado de docetaxel en el tratamiento del cáncer.
MX2021001764A (es) Terapia de combinacion.
ZA202201070B (en) Focal treatment of prostate cancer
MX393477B (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.
WO2018231799A8 (en) Methods of treating brain tumors using combination therapy
MX2024006078A (es) Metodo para tratar el cancer con acilfulveno y radiacion.
ATE442188T1 (de) Bestrahlungseinrichtung
MX2023011597A (es) Terapia combinada para el tratamiento del cáncer.
TW200724158A (en) Combination therapy in the treatment of cancer
EA202190294A1 (ru) Комбинированная терапия для лечения рака
MX2021001084A (es) Terapia de combinacion para el tratamiento del cancer.